HC Wainwright Boosts Zymeworks (NYSE:ZYME) Price Target to $13.00

Zymeworks (NYSE:ZYME - Free Report) had its price target upped by HC Wainwright from $12.00 to $13.00 in a research note released on Monday,Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Zymeworks' Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.

ZYME has been the subject of several other research reports. Citigroup raised their target price on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price for the company in a research note on Monday, December 16th. Finally, Wells Fargo & Company raised their price target on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Zymeworks currently has an average rating of "Moderate Buy" and an average price target of $21.00.

Zymeworks Trading Up 2.4 %

Shares of ZYME stock traded up $0.31 on Monday, hitting $12.86. 51,600 shares of the stock were exchanged, compared to its average volume of 478,048. The firm has a market capitalization of $894.41 million, a PE ratio of -8.67 and a beta of 1.13. Zymeworks has a one year low of $7.97 and a one year high of $17.70. The firm's 50 day moving average is $13.92 and its two-hundred day moving average is $13.64.

Remove Ads

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc purchased 11,958 shares of the company's stock in a transaction that occurred on Tuesday, December 24th. The shares were bought at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the completion of the transaction, the director now directly owns 14,704,239 shares of the company's stock, valued at $207,623,854.68. This trade represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $854,781.72. Following the completion of the transaction, the chief executive officer now owns 47,543 shares of the company's stock, valued at $709,341.56. This represents a 54.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 1,392,585 shares of company stock valued at $17,914,519 and have sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Zymeworks by 0.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company's stock worth $24,416,000 after purchasing an additional 14,604 shares during the last quarter. Deutsche Bank AG grew its position in Zymeworks by 1.2% during the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after buying an additional 17,849 shares during the period. State Street Corp grew its position in Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after buying an additional 67,401 shares during the period. Dimensional Fund Advisors LP grew its position in Zymeworks by 14.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock valued at $14,240,000 after buying an additional 123,240 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in Zymeworks by 2.3% during the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock valued at $11,121,000 after buying an additional 17,092 shares during the period. Institutional investors own 92.89% of the company's stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.